Biofrontera Inc. (BFRIW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Biofrontera Inc. operates as a biopharmaceutical entity dedicated to the commercialization of pharmaceutical products specifically designed for the treatment of dermatological conditions within the United States market. The company's portfolio includes the Ameluz product line alongside the BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are utilized for treating conditions such as actinic keratosis. Although specific sector and industry classifications are not disclosed in available public records, the organization functions within the specialized healthcare and medical device landscape, focusing on dermatological therapies. The company's scale is defined by a market capitalization that is not currently quantified in standard valuation metrics, an annual trailing twelve-month revenue of $41.70M, and an operational workforce of 84 employees. These figures indicate that Biofrontera functions as a mid-sized biopharmaceutical player with a revenue base sufficient to sustain significant research and development activities, though the lack of a traditional market cap valuation suggests a structure that may prioritize capital markets access over standard public trading liquidity.

वित्तीय स्वास्थ्य

Biofrontera reported a revenue of $41.70M for the trailing twelve months, yet this top-line performance is offset by a net income of -$10,536,000 and an EBITDA of -$11,210,000. The substantial gap between the $41.70M revenue and the negative net income reveals a cost structure where operating expenses, including research, development, and general administrative costs, significantly exceed current earnings before interest and taxes. The company generated a free cash flow of -$2,362,000, indicating a cash burn rate that necessitates continuous external capital raising to maintain operations and fund future product expansion. Despite the negative income, the company maintains a cash balance of $6.40M against total debt of $6.16M, creating a situation where liquid assets slightly exceed total liabilities. The debt-to-equity ratio stands at 58.79, which suggests a leveraged balance sheet structure rather than a conservative one, implying the company relies heavily on equity financing to manage its obligations. Liquidity is supported by a current ratio of 1.52, indicating that the company holds sufficient current assets to cover its short-term liabilities with a comfortable margin of safety. Furthermore, the return on equity is -141.3% and the return on assets is -28.0%, metrics that reveal management is currently not generating positive returns on the capital invested by shareholders or in total assets, a common characteristic for biopharmaceutical firms in the growth or development phase where reinvestment costs outpace immediate profitability.

मूल्यांकन आकलन

Trailing twelve-month P/E and forward P/E ratios are both unavailable due to the company's negative earnings, rendering traditional earnings-based valuation multiples inapplicable for assessing value at this time. In the absence of a positive P/E, the price-to-book ratio serves as a primary valuation metric, standing at 0.05, which indicates that the market values the company at a fraction of its net asset book value. This extremely low price-to-book ratio suggests the market prices the equity at a significant discount relative to the underlying assets recorded on the balance sheet. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also unavailable, as the company has not yet achieved profitability required to calculate meaningful earnings multiples. The stock trades within a narrow range with a 52-week high of $0.06 and a 52-week low of $0.05, meaning the current trading price is generally situated at or near the upper bound of this recent annual range. The beta value of 0.64 indicates that the stock exhibits lower volatility relative to the broader market, moving less dramatically than the S&P 500 in response to general market fluctuations.

Growth & Income

Biofrontera demonstrated a revenue growth rate of 36.2% year-over-year, while earnings growth is not applicable due to the company's persistent net losses. The disparity between the robust 36.2% revenue expansion and the negative earnings growth highlights a growth-at-any-cost strategy typical of early-stage biopharmaceuticals where sales volume increases faster than profitability. As the company does not pay dividends, indicated by the absence of a dividend yield and payout ratio, all available earnings and cash flows are theoretically directed toward reinvesting in product development rather than returning capital to shareholders. This reinvestment strategy is essential for funding the commercialization of its dermatological treatments and sustaining the high burn rates evident in its financial statements. The overall growth and income profile is characterized by rapid top-line expansion coupled with significant cash consumption and a lack of current income generation for investors.